Search results
Results from the WOW.Com Content Network
In 1935, PPH published "Frank Verulam's" 46 pages booklet titled "Imperialism and the People". [23] In 1939, PPH published Dona Torr’s 31 pages booklet "From Imperialist War to People's War". [24] In 1942, CPI rented a three-storey house "Raj Bhuvan" on the Sandhurst Road (now Sardar Vallabhbhai Patel Marg) of Bombay.
It is the first line treatment for PPH when its cause is the uterus not contracting well. [23] A combination of syntocinon and ergometrine is commonly used as part of active management of the third stage of labour. [24] This is called syntometrine. Syntocinon alone lowers the risk of PPH. [25]
Triphenylphosphine (IUPAC name: triphenylphosphane) is a common organophosphorus compound with the formula P(C 6 H 5) 3 and often abbreviated to P Ph 3 or Ph 3 P. It is versatile compound that is widely used as a reagent in organic synthesis and as a ligand for transition metal complexes, including ones that serve as catalysts in organometallic chemistry.
1,1,1-Tris(diphenylphosphinomethyl)ethane, also called Triphos, is an organophosphorus compound with the formula CH 3 C[CH 2 PPh 2] 3. An air-sensitive white solid, it is a tripodal ligand ("three-legged") of idealized C 3v symmetry. It was originally prepared by the reaction of sodium diphenylphosphide and CH 3 C(CH 2 Cl) 3: [1]
[RhH(CO)(PPh 3) 3] is a catalyst for the selective hydroformylation of 1-olefins to produce aldehydes at low pressures and mild temperatures. The selectivity for n-aldehydes increases in the presence of excess PPh 3 and at low CO partial pressures. [1] The first step in the hydroformylation process is the dissociative substitution of an alkene ...
Bis(triphenylphosphine)platinum chloride is a metal phosphine complex with the formula PtCl 2 [P(C 6 H 5) 3] 2.Cis- and trans isomers are known. The cis isomer is a white crystalline powder, while the trans isomer is yellow. [3]
Download as PDF; Printable version; ... -23.8 ±0.3: S=PMePh 2: 13639-74-2 PPh 3-21.5 ±0.3: S=PPh 3: 3878-45-3 References
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).